ASX:EMV

Stock Analysis Report

EMvision Medical Devices

Executive Summary

EMvision Medical Devices Limited engages in the research and development and commercializing imaging and diagnostic technology for the purpose of commercialising portable medical device for stroke diagnosis, monitoring, and other medical imaging needs.

Rewards

Revenue grew by 187.1% over the past year

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (A$1M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 2 more risks


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has EMvision Medical Devices's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EMV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

13.9%

EMV

-1.6%

AU Medical Equipment

1.5%

AU Market


1 Year Return

93.5%

EMV

36.7%

AU Medical Equipment

15.6%

AU Market

Return vs Industry: EMV exceeded the Australian Medical Equipment industry which returned 35.4% over the past year.

Return vs Market: EMV exceeded the Australian Market which returned 16.1% over the past year.


Shareholder returns

EMVIndustryMarket
7 Day13.9%-1.6%1.5%
30 Day11.1%1.3%0.4%
90 Day22.4%6.5%4.1%
1 Year93.5%93.5%39.0%36.7%20.6%15.6%
3 Yearn/a80.7%72.9%37.1%18.7%
5 Yearn/a121.3%104.0%50.9%17.1%

Price Volatility Vs. Market

How volatile is EMvision Medical Devices's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is EMvision Medical Devices undervalued compared to its fair value and its price relative to the market?

11.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EMV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EMV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EMV is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: EMV is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EMV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EMV is overvalued based on its PB Ratio (11.3x) compared to the AU Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is EMvision Medical Devices forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EMvision Medical Devices has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has EMvision Medical Devices performed over the past 5 years?

-250.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: EMV is currently unprofitable.

Growing Profit Margin: EMV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if EMV's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare EMV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EMV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.6%).


Return on Equity

High ROE: EMV has a negative Return on Equity (-64.29%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is EMvision Medical Devices's financial position?


Financial Position Analysis

Short Term Liabilities: EMV's short term assets (A$4.6M) exceed its short term liabilities (A$460.1K).

Long Term Liabilities: EMV has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: EMV is debt free.

Reducing Debt: EMV has not had any debt for past 5 years.


Balance Sheet

Inventory Level: EMV has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if EMV's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EMV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EMV has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -122.8% each year.


Next Steps

Dividend

What is EMvision Medical Devices's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.3%markettop25%5.5%industryaverage1.3%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate EMV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EMV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EMV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EMV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EMV's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average board tenure


CEO

Ron Weinberger 0

AU$444,168

Compensation

Dr. Ronald Peter Weinberger, also known as Ron, BSc (Hons), Ph.D., AIMM, serves as Non-Executive Chairman of HeraMED Limited and also has been its Director since August 21, 2018. Dr. Weinberger serves as C ...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD298.44K) is about average for companies of similar size in the Australian market ($USD254.67K).

Compensation vs Earnings: Insufficient data to compare Ron's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
John Keep
Executive Chairman0yrsAU$127.89k2.68% A$1.5m
Scott Kirkland
Executive Director2.6yrsAU$213.28k5.89% A$3.4m
Geoffrey Richard Pocock
Non-Executive Director1.9yrsAU$105.40k0.55% A$315.0k
Tony Keane
Non-Executive Director1.7yrsAU$74.09k0.16% A$90.0k
Ryan Laws
Non-Executive Director2.6yrsAU$97.21k5.2% A$3.0m
Stuart Crozier
Chairman of Clinical Advisory Board0.7yrsno data1.57% A$900.0k
Michael O'Sullivan
Member of Clinical Advisory Board0.7yrsno datano data
David Cook
Member of Clinical Advisory Board0.7yrsno datano data
James Walsham
Member of Clinical Advisory Board0.7yrsno datano data
Ken Mitchell
Member of Clinical Advisory Board0.7yrsno datano data

0.7yrs

Average Tenure

Experienced Board: EMV's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 127.7%.


Top Shareholders

Company Information

EMvision Medical Devices Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: EMvision Medical Devices Limited
  • Ticker: EMV
  • Exchange: ASX
  • Founded: 2017
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$57.294m
  • Shares outstanding: 63.66m
  • Website: https://www.emvision.com.au

Location

  • EMvision Medical Devices Limited
  • 72 Victoria Road
  • Rozelle
  • New South Wales
  • 2039
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EMVASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 2018
EMVCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 2018

Biography

EMvision Medical Devices Limited engages in the research and development and commercializing imaging and diagnostic technology for the purpose of commercialising portable medical device for stroke diagnosis, monitoring, and other medical imaging needs. It offers brain scanner, a portable clinical prototype that utilizes the EMvision technology to create three dimensional images of the human brain. The company has a strategic collaboration with Keysight Technologies Malaysia Sdn Bhd to develop a personalized vector network analysis solution for medical imaging in the healthcare sector. EMvision Medical Devices Limited was founded in 2017 and is based in Rozelle, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 10:51
End of Day Share Price2020/02/17 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.